We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gel Encapsulation Transport System Targets Disease-Related Cells

By LabMedica International staff writers
Posted on 10 Aug 2018
A novel therapeutic approach uses drugs encapsulated within galacto‐oligosaccharide gel capsules to target diseases that have accumulated a high percentage of senescent cells.

Senescent cells are aged or damaged cells that no longer are able to perform their normal roles. More...
These cells interfere with the functioning of the tissue in which they accumulate, and eliminating them is considered to be a promising therapeutic approach.

Investigators at the Institute for Research in Biomedicine (Barcelona, Spain) took advantage of the high lysosomal beta‐galactosidase activity of senescent cells to design a drug delivery system based on the encapsulation of drugs with galacto‐oligosaccharides and their delivery to lysosomes via endocytosis.

The investigators reported in the July 16, 2018, online edition of the journal EMBO Molecular Medicine that gal‐encapsulated fluorophores were preferentially released within senescent cells in mice. In a model of chemotherapy‐induced senescence, gal‐encapsulated cytotoxic drugs targeted senescent tumor cells and improved tumor xenograft regression in combination with the drug palbociclib.

In a model of pulmonary fibrosis in mice, gal‐encapsulated cytotoxic agents targeted senescent cells, reducing collagen deposition and restoring pulmonary function. In addition, gal‐encapsulation reduced the toxic side effects of the cytotoxic drugs. Thus, drug delivery into senescent cells opened new diagnostic and therapeutic applications for senescence‐associated disorders.

Senior author Dr. Manuel Serrano, head of the cellular plasticity and disease laboratory at the Institute for Research in Biomedicine, said, "This nanocarrier may pave the way for new therapeutic approaches for serious conditions, such as pulmonary fibrosis or to eliminate chemotherapy-induced senescent cells."

Related Links:
Institute for Research in Biomedicine


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.